May 27, 2026 04:04AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM
Mar 9, 2026 02:30AM
Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM FDA grants Priority Review to DATROWAY for metastatic breast cancer
Feb 3, 2026 02:30AM
Dec 2, 2025 09:18AM
Dec 2, 2025 09:18AM
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM
Sep 24, 2025 07:00AM
Sep 24, 2025 02:30AM ENHERTU® Plus Pertuzumab Granted Priority Review in the U.S. as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer
Jul 28, 2025 07:01AM
Jul 28, 2025 07:00AM
Jan 13, 2025 07:00AM
Jan 13, 2025 06:09AM
Jan 13, 2025 02:00AM
Dec 11, 2024 09:44AM
Dec 6, 2024 07:00AM IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
Dec 6, 2024 06:14AM
Oct 3, 2024 07:04AM
Oct 3, 2024 07:00AM
Oct 3, 2024 06:11AM
Oct 1, 2024 07:06AM
Oct 1, 2024 07:00AM
Oct 1, 2024 06:19AM AstraZeneca's (AZN) ENHERTU Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer
Oct 1, 2024 02:00AM
Sep 13, 2024 04:00AM
Aug 15, 2024 07:02AM
Aug 15, 2024 07:00AM
Jun 10, 2024 07:00AM
Jun 10, 2024 06:03AM
Jun 10, 2024 04:36AM AstraZeneca (AZN) announces Tagrisso granted FDA Priority Review for patients with unresectable, Stage III EGFR-mutated lung cancer
Apr 2, 2024 07:00AM
Apr 2, 2024 05:36AM
Apr 2, 2024 02:00AM
Feb 19, 2024 07:10AM
Feb 19, 2024 02:00AM
Jan 29, 2024 07:00AM
Jan 29, 2024 06:00AM AstraZeneca (AZN) Reports Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
Jan 29, 2024 02:00AM
Oct 24, 2023 07:00AM
Oct 24, 2023 05:46AM
Oct 16, 2023 07:00AM
Oct 16, 2023 06:16AM
Jul 28, 2023 07:05AM
Jun 12, 2023 07:00AM Capivasertib in combination with FASLODEX® (fulvestrant) granted Priority Review in the US for patients with advanced HR-positive breast cancer
Jun 12, 2023 05:32AM

15,458 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All